Back to results
US 11,891,363 B1Granted
Multi-target drug candidates for the treatment of triple-negative breast cancer
AssigneeKing Faisal University
InventorsSaad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
Life of this patent
Estimating the term…
Abstract
Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
Claims7
A multi-functional agent having the formula I:
- wherein:
- R1 is a C1—C6 alkyl group, a C2—C6 alkenyl group, an aryl group, a heteroaryl group, a C3—C8 cycloalkyl group, or a C3—C8 cycloalkenyl group;
- R2 is H, a C1—C6 alkyl group, a C2—C6 alkenyl group, an aryl group, a heteroaryl group, a C3—C8 cycloalkyl group, or a C3—C8 cycloalkenyl group;
- and
- R3 is a C1—C6 alkyl group, a C2—C6 alkenyl group, an aryl group, a heteroaryl group, a C3—C8 cycloalkyl group, or a C3—C8 cycloalkenyl group.
2 more elements
Dependencies are inferred from the claim text.